1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers

MACPAC ‘Undeterred’ By Lukewarm Reception Of Accelerated Drug Approval Recommendation

 
• By Cathy Kelly

Executive director Schwartz suggests Congress may turn its attention to the advisory commission’s proposal to revise Medicaid coverage for drugs approved under the accelerated approval pathway in the next year or two.

Medicaid Programs Concerned About Cost Of Accelerated Approval Drugs • Source: Alamy

The Medicaid and CHIP Payment and Access Commission remains hopeful about the implementation of its recommendation to Congress that Medicaid programs be given the authority to require differential rebates for drugs approved through the US Food and Drug Administration’s accelerated approval pathway despite a current lack of enthusiasm, according to MACPAC executive director Anne Schwartz.

In its June report to Congress, MACPAC recommended that Congress boost the Medicaid base rebate for accelerated approval drugs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicaid

More from Government Payers

Medicare Part D LIS Access Threatened By House Budget Bill’s Medicaid Obstacles

 
• By Cathy Kelly

An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.

Pharma’s Protests Fall Flat As UK Locks In High Rebate Rates

 
• By Neena Brizmohun

Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.